Insights: Bullish EAFE Stocks
Today's report is a bottom-up compilation of technically attractive, EAFE small-cap stocks, with one fundamental kicker: each name is accompanied by positive momentum in their FY EPS estimates... see screen on pages 12-15• We screened for stocks whose latest EPS estimate is higher than last week's, which in turn is greater than the prior month's estimate. From this list, which was rich in relative leaders, we picked out the names that were either (1) breaking out from, or (2) pulling back to base support levels... see charts on pages 2-11
• Group themes present in this screen:
• Bullish Auto Theme: The bullish auto trade--a global theme--remains intact. Two parts-related names that stand out in today's screen include: Plastic Omnium (POM-FR), a components stock, and Grammer (GMM-DE), a seat component manufacturer.
• Chemicals: Chemicals are a leading segment in our international Materials Sector. Tosoh Corp (4042-JP), a specialty chemicals name, is a buy.
• Cyclicals > Defense: It's true in our EPS momentum screens just as it's true in our top-down and bottom-up observations: cyclicals continue to outperform (overweight), and defense remains on the defensive (underweight).
For a trial to Vermilion Research, visit our website at www.vermilioncap.com or contact our sales team at (612) 315-4082.
Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.
Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.